Diabetic Foot News and Research

RSS

EO2 Concepts added to Marathon Medical's FSS contract

Electrochemical Oxygen Concepts, the developer of a unique and innovative chronic wound treatment device, announced it has been added to Marathon Medical's existing Federal Supply Schedule (FSS) contract, administered by The Department of Veterans Affairs.

11 May 2012

Cardionovum to introduce two DEB dilatation catheter product families

Cardionovum GmbH will launch two drug-eluting balloon (DEB) dilatation catheter product families at next week's EuroPCR 2012 congress: Paclitaxel-coated drug-eluting balloons for coronary and peripheral applications.

11 May 2012

Macrocure's CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial

Cell therapy demonstrates high rate of complete closure of hard-to-heal wounds, including diabetic foot (DFU) and venous ulcers.

10 May 2012

FDA clears Angioslide’s new 3X100mm PROTEUS device

Angioslide Ltd. a provider of Embolic Capture Angioplasty solutions, today announced that it has received FDA 510(K) clearance for its new 3X100mm PROTEUS device for treating Peripheral Artery Disease in below the knee (BTK) vasculature.

3 May 2012

Derma Sciences closes underwritten registered direct offering

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that it closed an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share on April 5, 2012.

9 Apr 2012

Cardium launches Excellagen wound care product

Cardium Therapeutics today announced market introduction of its Excellagen professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.

31 Mar 2012

Small electrical sensors can quickly detect MRSA infection

A simple test to identify MRSA in wounds could identify the superbug quickly and help prevent infection from spreading.

30 Mar 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Apixio introduces Clinical Knowledge Exchange at HIMSS 2012 conference

Apixio, Inc., the leading provider of clinical data integration, search and analytics for healthcare organizations, is introducing this week at the HIMSS 2012 conference, a technology framework called the Clinical Knowledge Exchange.

20 Feb 2012

Innocoll completes XaraColl End-of-Phase 2 meeting with FDA

Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.

17 Feb 2012

FDA issues order prohibiting certain uses of cephalosporins in food-producing animals

The U.S. Food and Drug Administration today issued an order that prohibits certain uses of the cephalosporin class of antimicrobial drugs in cattle, swine, chickens and turkeys effective April 5, 2012.

5 Jan 2012

IQWiG identifies additional recommendations for diabetes mellitus type 2 DMP

On 3 January 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes mellitus type 2.

4 Jan 2012

SANUWAVE Health third quarter revenues decrease 42% to $161,678

SANUWAVE Health, Inc. today reported financial results for the three and nine months ended September 30, 2011.

14 Nov 2011

APMA encourages 'Knock Your Socks Off' foot care campaign for people with diabetes

American Podiatric Medical Association Encourages Hispanic Health Awareness with "Knock Your Socks Off" Foot Care Campaign, Promotes Regular Foot Exams by Podiatrist to End Diabetes Complications

10 Nov 2011

Largest study on diabetes and foot ulcers

What's crucial for a diabetic's foot sore to heal is that the ulcer is superficial, blood circulation is normal, and the person has had diabetes for short time. This is shown in the world's largest diabetes study regarding foot ulcers, which has been carried out by the researcher Magdalena Annersten Gerhater at Malmö University in Sweden.

27 Oct 2011

FDA clears Cardium's new Excellagen topical gel for diabetic foot ulcers

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

11 Oct 2011

Cardium's Excellagen topical gel for diabetic foot ulcers receives FDA 510(k) clearance

Cardium Therapeutics announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell the Company's new Excellagen™ professional-use, sterile, syringe-based advanced wound care product for the management of diabetic foot ulcers and other dermal wounds.

10 Oct 2011

SANUWAVE announces dermaPACE Phase III trial results on diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that the Company's dermaPACE device will be the subject of a presentation at Plastic Surgery 2011, the American Society of Plastic Surgeons' National Meeting being held September 23-27 in Denver.

23 Sep 2011

Cardiff develops simple and effective wound test that could save NHS millions

Scientists in Cardiff are developing a simple but effective test to predict whether chronic wounds will respond to conventional treatment - which could save the NHS tens of millions of pounds annually.

20 Sep 2011

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011